Article    Full Text of this article    PDF of this article (PDFs free after 6 months) All Versions of this Article:    141/5/391 (most recent)    0000605-200409070-00100v1    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Doherty, R. B.    Related Articles in PubMed    PubMed Citation    PubMed

MEDICINE AND PUBLIC ISSUES

Assessing the New Medicare Prescription Drug Law

Robert B. Doherty, BA

7 September 2004 | Volume 141 Issue 5

The Medicare Modernization Act (MMA) is the product of a political compromise to attract moderate Republicans and enough Democrats without losing Republican conservatives. The compromise offered more private health plans to beneficiaries while maintaining and improving traditional Medicare's benefits. This compromise did not settle the debate over the legislation, which is a major issue in the 2004 elections. Voters poorly understand the law because of its complexity. In this paper, I explain how the policy decisions made by the U.S. Congress have contributed to the law's complexity and controversy. I examine the new private health plan options that will be offered to beneficiaries, improvements made to traditional Medicare, and the impact of introducing income-based determinations into Medicare. I also discuss the impact of the drug benefit on beneficiaries in different income and assets categories and Congress's decision to prohibit the federal government from directly negotiating prices with drug manufacturers. I conclude by assessing the major claims made by critics and proponents. Both might be more circumspect in their assessments of the law's impact, since it is impossible to predict how a law of such complexity, with so many human variables, will work out in the end. The MMA is a worthwhile but imperfect effort to extend drug coverage to seniors who are most in need. It deserves neither condemnation nor indiscriminate praise but instead a commitment to help it succeed.

Author and Article Information

From the American College of Physicians, Philadelphia, Pennsylvania.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Customer Service, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.

This article has been cited by other articles:

				W. Yin, A. Basu, J. X. Zhang, A. Rabbani, D. O. Meltzer, and G. C. Alexander The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures Ann Intern Med, February 5, 2008; 148(3): 169 - 177. [Abstract] [Full Text] [PDF]

				W. Shrank, J. Avorn, C. Rolon, and P. Shekelle Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review Ann. Pharmacother., May 1, 2007; 41(5): 783 - 801. [Abstract] [Full Text] [PDF]

				The USP Model Guidelines Expert Committee and U.S. Narrative review: the U.S. Pharmacopeia and model guidelines for Medicare Part D formularies. Ann Intern Med, September 19, 2006; 145(6): 448 - 453. [Abstract] [Full Text] [PDF]

				W. H Shrank, S. M Asch, G. J Joseph, H. N Young, S. L Ettner, Y. Kholodenko, P. Glassman, and R. L Kravitz Physicians' Perceived Knowledge of and Responsibility for Managing Patients' Out-of-Pocket Costs for Prescription Drugs Ann. Pharmacother., September 1, 2006; 40(9): 1534 - 1540. [Abstract] [Full Text] [PDF]

				W. H. Shrank, T. Hoang, S. L. Ettner, P. A. Glassman, K. Nair, D. DeLapp, J. Dirstine, J. Avorn, and S. M. Asch The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med, February 13, 2006; 166(3): 332 - 337. [Abstract] [Full Text] [PDF]

				E. M. DeWitt, H. A. Glick, D. A. Albert, M. M. Joffe, and F. Wolfe Medicare Coverage of Tumor Necrosis Factor {alpha} Inhibitors as an Influence on Physicians' Prescribing Behavior Arch Intern Med, January 9, 2006; 166(1): 57 - 63. [Abstract] [Full Text] [PDF]

				W. F. Gellad, H. A. Huskamp, K. A. Phillips, and J. S. Haas How The New Medicare Drug Benefit Could Affect Vulnerable Populations Health Aff., January 1, 2006; 25(1): 248 - 255. [Abstract] [Full Text] [PDF]

				D. E. Havrda, B. A. Omundsen, W. Bender, and M. A. Kirkpatrick Impact of the Medicare Modernization Act on Low-Income Persons Ann Intern Med, October 18, 2005; 143(8): 600 - 608. [Abstract] [Full Text] [PDF]

				G. Nichol, P. Kaul, E. Huszti, and J. F.P. Bridges Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure Ann Intern Med, September 7, 2004; 141(5): 343 - 351. [Abstract] [Full Text] [PDF]

				M. A. Hlatky and B. M. Massie Cardiac Resynchronization for Heart Failure Ann Intern Med, August 16, 2004; (2004) 0000605-200409070-00105. [Full Text] [PDF]